Start Services Company Profile Publications Jobs Customers Contact

vivacell_graurotbuttonklein  Recent news

September 2016

Cooperation with Dhofar University (Sultanate of Oman)

 

May 2016

We were awarded the Stifterverband's "Innovative through Research" for our research activities.

 

April 2016

New Version of SimDerma including 30 important dermato-cosmetic parameters.

Read more here.

 

November 2015:

New Services in neurotoxicity and neuroprotection

Read more here.

 

October 2015:

SimDerma - new screening platform for cosmetic ingredients.

simderma_werbefoto

Read more here.

 

Services in Oral Care.

Read more here.

 

September 2015:

Please have a look at our new services in miRNA research.

Read more here.

 


 

New publications by VivaCell:

 

"Poly(I:C) increases the expression of mPGES-1 and COX-2 in rat primary
microglia."

in J Neuroinflamm. 2016 Jan

 

"Antimalarial Drug Artemether Inhibits Neuroinflammation in BV2 Microglia
Through Nrf2-Dependent Mechanisms."

in Mol Neurobiol. 2015 Nov

 

"microRNA-26a modulates inflammatory response induced by toll-like receptor 4 stimulation in microglia."

in J Neurochem, 2015 Sep

 

"Anti-inflammatory effects of 5-HT3 receptor antagonists in interleukin-1beta stimulated primary human chondrocytes."
in Int Immunopharmacol. 2014 Jun

"Histone deacetylase inhibitors valproic acid and sodium butyrate enhance prostaglandins release in lipopolysaccharide-activated primary microglia."
Neuroscience. 2014 Jan 28

 

 

Read more news...

 

 

vivacell_graurotbuttonklein  Opinions from our customers:

p-pascoe-naturmedizin

Dr. G. Weiss (PASCOE pharmazeutische Praeparate GmbH):

:

"During our well going cooperation over several years, we learned to appreciate VivaCell as a reliable and competent co-operation partner in pre-clinical research. Therefore we are looking forward to continue our successful partnership."  

 

 

Read more
opinions...

 

 

Phytodrug / Nutraceuticals
Immunomodulation
Cardiovascular inflammation
Oncology / Angiogenesis
Oral care
Central Nervous System
Microglia activation studies
Electrophysiological. Meas.
Dermatology / Cosmetics
Muscle
HIV-1 / AIDS
Diabetes
ADME
Permeability Studies
Toxicology
Urinary / Prostata
Animal health
Additional Services
Quality Certificate
SimDerma / Cosmetics
Neurotox testing / Protection
miRNA
Services in Oral Care

 

We are awarded for our R&D activities by the Stifterverband:

 

forschung_und_entwicklung_2016_web

 

 


 

We are proud members of:

 

logo_biovalley

    koop-phyto-logo

ga 

 

logo_bpl-rgb_klein-web

 


 

VivaCell Quality-Certificate:

 

vivacellqualitycertificateenglish

 

Read more ...

in vitro models to test 5a-Reductase Inhibition (prostata) 

 

 

Biochemistry

 

5a reductase (3-oxo-5a-steroid-D4-dehydrogenase; 5aR), a NADPH-dependent membrane protein, irreversibly catalyses the reduction of 4-en-3-oxosteroids, resulting in the corresponding 5a-3-oxosteroids. The most important reaction is the conversion of testosterone (T) to the most potentandrogen 5a-dihydrotestosterone (DHT), which displays the highest affinity towards the androgen receptor. The irreversible reduction of T to DHT represents the final step in androgen biosynthesis. In humans, two 5a reductase isoenyzme are expressed: 5a reductase type I and 5a reductase type II. The isoenzymes have a different distribution pattern, which is still under discussion. In principle, type I is predominantly expressed in skin, scalp and follicles, whereas type II is mainly found in prostate tissue. However, more recent reports describe that 5a reductase I is the predominant form in oil and sweat glands. In stroma and basal cells of the prostate, 5a reductase type II is expressed, but Shirakawa et al. (2004) demonstrated that in epithelial cells of the prostate, also 5a reductase I is expressed. 5a-reductase type I and type II display distinct biochemical and pharmacological properties, such as pH-optimum, Km etc.

 

Pathophysiology

Elevated DHT levels correlate with the pathogenesis and progression of androgen-dependent diseases such as prostate cancer (PCa) and benign prostatic hyperplasia (BPH), which is the most common benign tumor affecting over 50% of men above the age of 70. Both conditions have been successfully treated with drugs that lower the level of DHT available to prostate tissue, so-called 5a reductase inhibitors, blocking the action of the enzyme 5a reductase that converts T into DHT.

 

At VivaCell, we offer to test compounds or extracts for in vitro 5a-Reductase Inhibition (Type I and Type II)

 

Literature:

Shirakawa T.; Okada H.; Acharya B.; Zhang Z.; Hinata N. et al. Messenger RNA levels and enzyme activities of 5 alpha-reductase types 1 and 2 in human benign prostatic hyperplasia (BPH) tissue. Prostate 2004, 58, 33-40.

 

 

 

 

 

 

       Sprache         Language          Idioma

germanenglishspanish